The West Health Institute has hit the ground running under the leadership of the organization’s new CEO.

Since formally assuming day-to-day control of the San Diego based NGO on September 5th, Nicholas J. Valeriani has pressed ahead on several deals that have presumably been stuck in a holding pattern for the last several months as the Institute underwent a simultaneous rebranding and search for a new chief executive.

Last week the West Health Investment Fund announced two new early stage investments in startups RxAnte and GlySens.

“Through targeted external investments in companies focused in advancing cost-effective and cost-saving models of care, West Health can impact the cost of health care in the country,” said Nicholas J. Valeriani, chief executive of West Health. “These two innovative companies highlight the kinds of new approaches to diabetes treatment and medication adherence that have great potential to disrupt the current delivery model and lower the cost of health care.”

Virginia-based RxAnte is a medication adherence startup that uses predictive analytics to identify the most effective outreach method and ensure that their patients take their medications as directed by their health care professional. West made the investment in RxAnte alongside Aberdare Ventures.

“Adherence to prescribed medicine is a critical issue for a variety of health care organizations, and one of the biggest opportunities to improve health care,” said Dr. Josh Benner, Founder and CEO of RxAnte. “RxAnte has pioneered a promising new approach to getting the right adherence interventions to the right patients at the right time. In collaboration with Aberdare and West Health, we’re excited to expand our offerings and help more organizations achieve higher quality care at lower cost.”

GlySens uses a long term, fully implanted sensor that is unobtrusive and functions automatically and continuously, transmitting its signal wirelessly to points of need. The device relies on two separate sensors, a glucose sensor in which a selective chemical reaction, involving glucose and oxygen, is measured by an electrochemical oxygen detector, and an oxygen reference sensor to detect tissue oxygen. By automatically calculating the difference between the signals from these two sensors, the device determines glucose levels.

An important advantage of this type of sensor system is the capability to warn of hypoglycemia, glucose levels that are dangerously low.

“Patients get no benefit from drugs they do not take, complex regimens they cannot follow, or care they cannot afford,” said Dr. Joseph Smith, chief medical and science officer of West Health. “These investments reflect our commitment to increasing the efficiency of health care delivery while decreasing the burdens of complexity and cost.”